Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/117470) titled 'Study to Assess the Effectiveness and Safety of Habbe Suranjan in Patients with Stable Coronary Artery Disease' on Sept. 10.
Study Type: Interventional
Study Design:
Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Random Number Table Method of allocation concealment:Case Record Numbers Blinding and masking:Participant Blinded
Primary Sponsor: CCRUM Ministry of AYUSH
Condition:
Health Condition 1: I708- Atherosclerosis of other arteries
Intervention:
Intervention1: Habbe e suranajan: Habbe e suranjan 1gm twice daily means 2 tablets of 500 mg each after...